Sharemaestro company-news research for Arcturus Therapeutics Holdings Inc (ARCT), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

NASDAQ United States Provisional evidence

Company news sentiment

Latest ARCT news and sentiment

Arcturus Therapeutics Holdings Inc

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report Factor research Options activity RSS feed
30-day score53Neutral is 50
Early balanced news score 23/100 evidence confidence 98% direct company focus 36 current stories across 10 publishers
Latest weekly closeUSD 15.19week of 28 Aug 2026
Main news subjectEarnings79/100 share of current news
News data statusHealthy50 duplicate stories removed

Current company news

Early balanced news score

36 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.

Observed headline tone63/100 Published 30-day score53/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy? Zacks · 27 Aug 2026 13:55

What supports the score

Direct evidence

36 current stories are mapped specifically to ARCT.

Source breadth

The score uses 10 publishers rather than depending on one outlet.

What limits the score

Too little evidence

The stories agree, but freshness-weighted evidence is only 0.243.

Confidence

Confidence is 23/100, below the threshold for a firm score.

53/100
News scoreEarly balanced news score
23/100
Confidencethin evidence
98%/100
Company news36 company stories
88/100
Story agreement12/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence
02 Aug: 2 stories04 Aug: 1 stories05 Aug: 2 stories06 Aug: 4 stories07 Aug: 6 stories08 Aug: 1 stories09 Aug: 1 stories11 Aug: 1 stories12 Aug: 1 stories13 Aug: 1 stories14 Aug: 1 stories16 Aug: 2 stories17 Aug: 1 stories19 Aug: 2 stories22 Aug: 1 stories23 Aug: 1 stories25 Aug: 1 stories27 Aug: 1 stories 02 Aug: tone 43, 2 stories04 Aug: tone 41, 1 stories05 Aug: tone 43, 2 stories06 Aug: tone 56, 4 stories07 Aug: tone 60, 6 stories08 Aug: tone 60, 1 stories09 Aug: tone 42, 1 stories11 Aug: tone 50, 1 stories12 Aug: tone 50, 1 stories13 Aug: tone 50, 1 stories14 Aug: tone 50, 1 stories16 Aug: tone 45, 2 stories17 Aug: tone 50, 1 stories19 Aug: tone 68, 2 stories22 Aug: tone 50, 1 stories23 Aug: tone 50, 1 stories25 Aug: tone 50, 1 stories27 Aug: tone 50, 1 stories 95505
01 Aug16 Aug30 Aug
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence5
0.243 after freshness weighting
Source breadth100
10 independent publishers
Company relevance98
share tied directly to this company
Freshness21
recency-weighted evidence
Agreement88
how closely stories agree
Publisher mix81
less reliance on one publisher

Price and news history

Weekly price and news-score history

Early company-news score

Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.

26 completed price weeks20 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
06 Mar 2026: close 7.11, indexed 100.013 Mar 2026: close 6.68, indexed 94.020 Mar 2026: close 6.63, indexed 93.227 Mar 2026: close 6.76, indexed 95.103 Apr 2026: close 8.03, indexed 112.910 Apr 2026: close 8.36, indexed 117.617 Apr 2026: close 8.85, indexed 124.524 Apr 2026: close 8.59, indexed 120.801 May 2026: close 8.63, indexed 121.408 May 2026: close 9.22, indexed 129.715 May 2026: close 7.47, indexed 105.122 May 2026: close 7.03, indexed 98.929 May 2026: close 7.92, indexed 111.405 Jun 2026: close 7.3, indexed 102.712 Jun 2026: close 6.97, indexed 98.019 Jun 2026: close 7.53, indexed 105.926 Jun 2026: close 6.88, indexed 96.803 Jul 2026: close 7.28, indexed 102.410 Jul 2026: close 6.97, indexed 98.017 Jul 2026: close 6.05, indexed 85.124 Jul 2026: close 5.53, indexed 77.831 Jul 2026: close 5.76, indexed 81.007 Aug 2026: close 7.41, indexed 104.214 Aug 2026: close 8.23, indexed 115.821 Aug 2026: close 13.45, indexed 189.228 Aug 2026: close 15.19, indexed 213.6 06 Mar 2026: news score 47, close 7.11, 3 stories4713 Mar 2026: news score 50, close 6.68, 3 stories20 Mar 2026: news score 50, close 6.63, 3 stories27 Mar 2026: news score 50, close 6.76, 3 stories5003 Apr 2026: news score 50, close 8.03, 1 stories08 May 2026: news score 53, close 9.22, 5 stories15 May 2026: news score 51, close 7.47, 6 stories5122 May 2026: news score 51, close 7.03, 6 stories29 May 2026: news score 50, close 7.92, 6 stories05 Jun 2026: news score 50, close 7.3, 5 stories5026 Jun 2026: news score 55, close 6.88, 3 stories03 Jul 2026: news score 53, close 7.28, 8 stories10 Jul 2026: news score 52, close 6.97, 10 stories5217 Jul 2026: news score 53, close 6.05, 11 stories24 Jul 2026: news score 48, close 5.53, 16 stories31 Jul 2026: news score 54, close 5.76, 26 stories5407 Aug 2026: news score 55, close 7.41, 38 stories14 Aug 2026: news score 52, close 8.23, 42 stories21 Aug 2026: news score 54, close 13.45, 44 stories5428 Aug 2026: news score 52, close 15.19, 32 stories52 Price index 229.9 145.7 61.5 News score 100 50 0
06 Mar02 Jun28 Aug
Weekly close, indexedSentiment score
26-week price+113.6%latest close 15.19
News score change+5first to latest comparable week
One-week response+63.4%Price confirming higher
Fair-value position-24.8%Below fair value
WeekNews scoreCloseWeekly move
28 Aug 202652USD 15.19+12.9%
21 Aug 202654USD 13.45+63.4%
14 Aug 202652USD 8.23+11.1%
07 Aug 202655USD 7.41+28.6%
31 Jul 202654USD 5.76+4.2%
24 Jul 202648USD 5.53-8.6%
17 Jul 202653USD 6.05-13.2%
10 Jul 202652USD 6.97-4.3%
Provisional evidence

News subjects

What is shaping the score

Earnings
Earnings6019 stories · 53%
Analyst action517 stories · 19%
Market update506 stories · 17%
Balance sheet542 stories · 6%
Guidance482 stories · 6%

Source mix

Where the evidence comes from

81/100 independence
MarketBeat565 stories · 14%
TradingView434 stories · 11%
Moomoo524 stories · 11%
vinanet.vn504 stories · 11%
Zacks563 stories · 8%
StocksToTrade602 stories · 6%
Stock Traders Daily442 stories · 6%

Recurring subjects

Subjects appearing most often

Current evidence
Life Sciences17Earnings13Financial Markets11Finance5Biotech2Fourth Quarter1Earnings Surprise1Earnings Report1Earnings Release1Earnings Estimate1

Earlier readings

How the score has changed

41 comparable readings · 115 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move+250 to 52 · Broadly stable
Observed range48–5650 is the neutral baseline
Evidence depth31stories at latest stored reading · +30
Confidence20/100Provisional · +20
06 May50 neutral30 Aug 05:01
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
30 Aug 05:0152+020/100 (-2)31 (-6)Provisional
27 Aug 23:5952-122/100 (-2)37 (-3)Provisional
25 Aug 23:5953-124/100 (-2)40 (-2)Provisional
23 Aug 23:5954+026/100 (-2)42 (-1)Provisional
22 Aug 23:5954-128/100 (-6)43 (-3)Provisional
19 Aug 23:5955+334/100 (+9)46 (+2)Provisional
17 Aug 23:5952+025/100 (-1)44 (+1)Provisional
16 Aug 23:5952+026/100 (-4)43 (+1)Provisional

Source headlines

The news behind the score

Showing 1-30 of 36

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

#1—Not directional
ZacksDirect company coverageScored from headline

Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?

Published
27 Aug 2026 13:55
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 0.6d old
Duplicates
1 consolidated
#2—Not directional
CNNDirect company coverageScored from headline

ARCT Stock Quote Price and Forecast

Published
25 Aug 2026 08:02
News subject
Guidance
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 2.8d old
Duplicates
1 consolidated
#3—Not directional
vinanet.vnDirect company coverageScored from headline

Arcturus (ARCT) Results Check: EPS Clears the Reported Estimate; Market Response: Shares Finish 22.38% Up for the Current Session - Earnings Power Value

Published
23 Aug 2026 14:30
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 4.5d old
Duplicates
1 consolidated
#4—Not directional
StocksToTradeDirect company coverageStored article

Arcturus Therapeutics Holdings Inc. (ARCT) Stock Price | Live Quotes & Charts | NASDAQ

Arcturus Therapeutics Holdings Inc. (ARCT) saw a significant price increase of 23.12%, adding $2.54 to its stock value. The article provides live quotes and charts for ARCT but notes that there is no current analyst rating data or earnings information available for the company. It also includes disclaimers about investment risks and the informational nature of the content.

EarningsFinancial MarketsLife Sciences
Published
22 Aug 2026 00:40
News subject
Analyst action
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 6.1d old
Duplicates
1 consolidated
#563Tone
StocksToTradeDirect company coverageStored article

ARCT Stock Jumps As Vaccine Rights Return And Cash Pile Grows

Arcturus Therapeutics stock (ARCT) surged nearly 20% due to positive sentiment surrounding its mRNA pipeline, including the regaining of global rights to its KOSTAIVE vaccine and a growing cash reserve of $191.5 million. Despite a slight revenue miss and continued losses in Q2, the company's strong balance sheet and advancing Phase 2 trials for ARCT-032 and ARCT-810 are providing catalysts for traders. Analysts maintain a "Buy" rating, seeing the recent collaboration changes and cash injection as beneficial for the company's future.

EarningsFinancial MarketsLife Sciences
Published
19 Aug 2026 13:41
News subject
Earnings
Why this score
Positive market reaction, Large positive market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 48/100
30-day weight
30.7% of the score · 8.6d old
Duplicates
1 consolidated
#8—Not directional
AOL.comDirect company coverageScored from headline

Arcturus (ARCT) Q2 2026 Earnings Call Transcript

Published
16 Aug 2026 14:26
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 11.5d old
Duplicates
1 consolidated
#9—Not directional
Stock Traders DailyDirect company coverageStored article

Liquidity Mapping Around (ARCT) Price Events

This article analyzes Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) using AI models, identifying strong near and mid-term sentiment but a weak long-term outlook. It highlights a significant risk-reward short setup and provides specific trading strategies (Long, Momentum Breakout, Risk Hedging) with entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strength, support, and resistance levels for ARCT.

Financial MarketsLife Sciences
Published
16 Aug 2026 08:38
News subject
Guidance
Why this score
Weak guidance
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 11.8d old
Duplicates
1 consolidated
#10—Not directional
MoomooDirect company coverageStored article

We're Keeping An Eye On Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate

This article examines Arcturus Therapeutics Holdings' cash burn rate and its implications for the company's future. It highlights the company's current cash reserves and how long they might last given its operating expenses. The analysis is crucial for investors to understand the company's financial health and potential need for future funding.

EarningsLife Sciences
Published
14 Aug 2026 19:10
News subject
Balance sheet
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 13.3d old
Duplicates
1 consolidated
#11—Not directional
MarketBeatDirect company coverageScored from headline

HC Wainwright Has Optimistic Outlook of ARCT Q3 Earnings

Published
13 Aug 2026 07:00
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 14.9d old
Duplicates
1 consolidated
#12—Not directional
TradingViewDirect company coverageStored article

Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline

Arcturus Therapeutics is focusing its mRNA platform on rare diseases like cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency, utilizing its vaccine business to fund these therapeutic developments. The company expects to decide on advancing its inhaled mRNA treatment for CF (ARCT-032) into Phase III in the fourth quarter, based on ongoing Phase II data. Additionally, Arcturus anticipates reporting data and regulatory updates for its injectable mRNA therapy for OTC deficiency (ARCT-810) before September 30, while maintaining a cash runway through 2028.

Life Sciences
Published
12 Aug 2026 02:10
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 16.1d old
Duplicates
2 consolidated
#13—Not directional
MoomooDirect company coverageStored article

H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Hold Rating, Maintains Target Price $9

H.C. Wainwright has reiterated its Hold rating on Arcturus Therapeutics (ARCT.US) and maintained its target price at $9. This indicates that the firm sees the stock as likely to perform in line with the broader market and does not anticipate significant price movement from current levels.

FinanceLife Sciences
Published
11 Aug 2026 20:12
News subject
Analyst action
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 16.3d old
Duplicates
1 consolidated
#1442Tone
MarketBeatDirect company coverageStored article

Arcturus Therapeutics (NASDAQ:ARCT) Rating Increased to Sell at Wall Street Zen

Wall Street Zen upgraded Arcturus Therapeutics (ARCT) from "strong sell" to "sell," while Weiss Ratings maintained its "sell (D-)" rating. Despite these downgrades, MarketBeat's analyst consensus remains a "Moderate Buy" with an average price target of $24.25. The clinical-stage biotech company, which develops mRNA medicines and vaccines, reported a quarterly loss of $0.84 per share, beating expectations, but revenue of $2.96 million missed estimates.

EarningsFinanceFinancial MarketsLife Sciences
Published
09 Aug 2026 09:12
News subject
Earnings
Why this score
Missed expectations
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Low · 35/100
30-day weight
5% of the score · 18.8d old
Duplicates
1 consolidated
#1560Tone
simplywall.stDirect company coverageScored from headline

Arcturus Therapeutics (ARCT) Stock Jumps As Cash Runway Reframes Pipeline Risk

Published
08 Aug 2026 07:00
News subject
Balance sheet
Why this score
Positive market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 39/100
30-day weight
9.7% of the score · 19.9d old
Duplicates
1 consolidated
#1636Tone
TradingViewDirect company coverageStored article

Arcturus Therapeutics Holdings Inc. Stock 12‑Month Price Target Cut to $20.2, Implies 232% Upside

Arcturus Therapeutics Holdings Inc.'s average stock price target has been reduced from $20.6 to $20.2 by 10 analysts, still suggesting a significant 232% potential upside based on its closing price on August 6. Despite the target cut, the consensus rating from 13 analysts remains a "Buy," with 10 recommending Buy, 3 Hold, and 0 Sell. Investors can find more detailed price target data and analyst recommendations on TradingView's platform.

Financial MarketsLife Sciences
Published
07 Aug 2026 23:39
News subject
Analyst action
Why this score
Analyst downgrade
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 37/100
30-day weight
0.7% of the score · 20.2d old
Duplicates
1 consolidated
#1768Tone
MoomooDirect company coverageScored from headlineSource lookup

William Blair Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating

Published
07 Aug 2026 16:58
News subject
Analyst action
Why this score
Buy Rating
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 40/100
30-day weight
0.5% of the score · 20.4d old
Duplicates
1 consolidated
#1874Tone
MoomooDirect company coverageStored article

CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Cuts Target Price to $20

CCORF has reiterated its Buy rating for Arcturus Therapeutics (ARCT.US) but has adjusted its target price downwards to $20. This indicates a continued positive outlook on the stock, albeit with a revised valuation.

EarningsFinanceFinancial MarketsLife Sciences
Published
07 Aug 2026 12:10
News subject
Analyst action
Why this score
Buy Rating
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 48/100
30-day weight
0.8% of the score · 20.6d old
Duplicates
3 consolidated
#19—Not directional
BioSpaceDirect company coverageStored article

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

Arcturus Therapeutics reported its Q2 2026 financial results and provided updates on its pipeline, including continued progress in the ARCT-032 Phase 2 cystic fibrosis study and completed enrollment for the ARCT-810 Phase 2 OTC deficiency study. The company regained global rights to KOSTAIVE® and its infectious disease vaccine portfolio, receiving $12 million in cash and $16 million in released liabilities. Despite a decrease in revenue compared to the previous year, Arcturus maintains a strong cash position with a runway through 2028, supported by strategic collaborations and a focus on rare disease programs.

EarningsFinanceLife Sciences
Published
07 Aug 2026 11:10
News subject
Earnings
Why this score
Positive financial language
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 20.7d old
Duplicates
2 consolidated
#2075Tone
MarketBeatDirect company coverageStored article

Arcturus Therapeutics (NASDAQ:ARCT) Announces Earnings Results, Beats Estimates By $0.16 EPS

Arcturus Therapeutics (NASDAQ:ARCT) announced its quarterly earnings, reporting an EPS of ($0.84), beating analyst estimates by $0.16, despite revenue of $2.96 million falling short of expectations. The company provided updates on clinical trials for ARCT-810 and ARCT-032, and regained global rights to its KOSTAIVE vaccine portfolio after ending a collaboration with CSL. Despite a sharp decline in revenue and cash, the company states it has sufficient cash runway through 2028.

EarningsFinancial MarketsLife Sciences
Published
07 Aug 2026 07:00
News subject
Earnings
Why this score
Beat expectations
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 52/100
30-day weight
5.7% of the score · 20.9d old
Duplicates
2 consolidated
#2143Tone
Investing.comDirect company coverageStored article

Earnings call transcript: Arcturus Therapeutics tops Q2 2026 EPS view

Arcturus Therapeutics reported a narrower-than-expected loss for Q2 2026, beating EPS forecasts by 20%, but saw a significant revenue drop due to the conclusion of its CSL Seqirus collaboration. The company emphasized progress in its rare disease pipeline, including cystic fibrosis (ARCT-032) and ornithine transcarbamylase deficiency (ARCT-810) programs, with key clinical milestones expected later in 2026. Arcturus also regained global rights to its KOSTAIVE COVID-19 vaccine and broader self-amplifying mRNA platform, exploring new commercialization and partnering opportunities.

BiotechClinical TrialsEarningsFinanceFinancial MarketsFourth Quarter
Published
07 Aug 2026 00:10
News subject
Earnings
Why this score
Operating deterioration
Company focus
Shared story · 78%
How it is used
Direct company coverage
Story strength
Low · 30/100
30-day weight
3.7% of the score · 21.1d old
Duplicates
6 consolidated
#2239Tone
TradingViewDirect company coverageStored article

Arcturus Therapeutics Holdings Inc. Q2 2026: Revenue $2.96M, EPS $(0.84) — 10-Q Summary

Arcturus Therapeutics Holdings Inc. (ARCT) reported its Q2 2026 financial results, with revenue of $2.96 million and a net loss of $23.79 million, resulting in a diluted loss per share of $(0.84). This decline in revenue is attributed to KOSTAIVE transitioning to commercial stages, leading to a significant drop in collaboration and grant revenue. Despite the financial decline, the company highlighted product momentum with KOSTAIVE's approval in Japan, ongoing clinical progress for ARCT-032 and ARCT-810, and strategic manufacturing partnerships.

EarningsLife Sciences
Published
06 Aug 2026 23:39
News subject
Earnings
Why this score
Operating deterioration
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 38/100
30-day weight
4.1% of the score · 21.2d old
Duplicates
1 consolidated
#2370Tone
ZacksDirect company coverageStored article

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates

Arcturus Therapeutics (ARCT) reported a Q2 loss of $0.84 per share, surpassing the Zacks Consensus Estimate of a $1.07 loss, and beat revenue estimates with $2.96 million. Despite underperforming the S&P 500 year-to-date, the company has exceeded EPS estimates in three of the last four quarters. The stock currently holds a Zacks Rank #3 (Hold), suggesting it will perform in line with the market.

EarningsFinancial MarketsLife Sciences
Published
06 Aug 2026 21:20
News subject
Earnings
Why this score
Beat expectations
Company focus
Shared story · 78%
How it is used
Direct company coverage
Story strength
Medium · 45/100
30-day weight
5.3% of the score · 21.3d old
Duplicates
3 consolidated
#24—Not directional
marketscreener.comDirect company coverageScored from headline

Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Published
06 Aug 2026 07:00
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 21.9d old
Duplicates
1 consolidated
#25—Not directional
AOL.comDirect company coverageScored from headline

Arcturus Therapeutics: Q2 Earnings Snapshot

Published
06 Aug 2026 07:00
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 21.9d old
Duplicates
1 consolidated
#26—Not directional
Stock Traders DailyDirect company coverageStored article

Why (ARCT) Price Action Is Critical for Tactical Trading

The article discusses the critical price action for Arcturus Therapeutics Holdings Inc. (ARCT) for tactical trading, highlighting a near-term strong sentiment that could challenge persistent mid and long-term weakness. It identifies an exceptional 394.0:1 risk-reward setup targeting a 90.6% gain versus 0.2% risk and provides three distinct institutional trading strategies based on AI models: Position, Momentum Breakout, and Risk Hedging. The analysis also includes a multi-timeframe signal analysis indicating support and resistance levels across different time horizons.

Financial MarketsLife Sciences
Published
05 Aug 2026 21:41
News subject
Market update
Why this score
Positive financial language
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 22.2d old
Duplicates
1 consolidated
#2841Tone
TradingViewDirect company coverageStored article

Arcturus Therapeutics Holdings Inc expected to post a loss of 100 cents a share - Earnings Preview

Arcturus Therapeutics Holdings Inc (ARCT) is anticipated to report a loss of 100 cents per share in its upcoming earnings. This forecast is part of an earnings preview, suggesting investors and analysts are closely watching the company's financial performance. The full article provides more in-depth analysis from Reuters, accessible through a TradingView subscription.

EarningsLife Sciences
Published
04 Aug 2026 21:47
News subject
Earnings
Why this score
Negative financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Low · 34/100
30-day weight
2.4% of the score · 23.2d old
Duplicates
1 consolidated
#30—Not directional
TradingKeyDirect company coverageScored from headlineSource lookup

Arcturus Therapeutics Holdings Inc (ARCT) Valuation: PE, PB & Fair Value Analysis

Published
02 Aug 2026 04:54
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 25.9d old
Duplicates
1 consolidated

Earlier company news

ARCT news archive

37 older headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Older news is kept in the archive

There are 37 older ARCT headlines. Open one page at a time when you need them.

Open older archive

Provider matches checked

Provider mentions not used in the score

2 not scored

A news provider linked these stories to ARCT, but the headline and available text are not mainly about Arcturus Therapeutics Holdings Inc. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.

Provider mentions are kept separate

Open the list to see which provider matches were checked and left out of ARCT sentiment.

Open provider mentions

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context